ACR 2022 Tweet by Md Yuzaiful Md Yusof

Professor van Vollenhoven has compiled a state-of-the-art review on lupus treatment advances – current and future. SLE management is entering an unprecedented phase.

An economic evaluation of early vs delayed use of the Blys inhibitor, belimumab (BEL), in systemic lupus erythematosus (SLE) has shown both cost effectiveness and clinical utility of early BEL initiation in active lupus patients.While most would advocate for using your best therapy first when…

There are so many SLE trials, and over the last year, many new ideas have been suggested.